Related Experiment Videos
Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice
1Department of Immunology, Institute of Biostructure, The Medical University of Warsaw, Poland. jgolab@ib.amwaw.edu.pl
Abstract:
Nonsteroidal anti-inflammatory drugs have been shown to reduce the incidence and mortality from colorectal cancer. It has recently been demonstrated that these drugs are capable of suppressing the production of pro-angiogenic factors from tumor cells. The mechanisms of antitumor action of interleukin 12 include the enforced secretion of anti-angiogenic factors and stimulation of antitumor immunity. Therefore, we hypothesized that the combination of a model nonsteroidal anti-inflammatory drug--indomethacin and interleukin 12--would result in enhanced angiogenesis-dependent antitumor effects against a colon-26 carcinoma cells transplanted into syngeneic mice. As expected the combined administration of both agents simultaneously resulted in a strengthened antitumor activity that was manifested as a retardation of tumor growth and prolongation of mouse survival. Importantly some mice were completely cured after the combined treatment. As administration of interleukin 12 and indomethacin resulted in enhanced inhibition of angiogenesis it seems possible that prevention of new blood vessel formation is one of the mechanisms responsible for the observed antitumor effects.
Insights
Combining nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin with interleukin 12 enhances anti-tumor effects by inhibiting blood vessel formation, leading to slower tumor growth and improved survival in mice.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to reduce colorectal cancer incidence and mortality.
- NSAIDs can suppress pro-angiogenic factors produced by tumor cells.
- Interleukin 12 (IL-12) exhibits anti-tumor effects through anti-angiogenic factor secretion and immune stimulation.
Purpose of the Study:
- To investigate the combined effect of indomethacin (a model NSAID) and IL-12 on angiogenesis-dependent anti-tumor activity.
- To evaluate the efficacy of this combination against colon-26 carcinoma in a syngeneic mouse model.
Main Methods:
- Simultaneous administration of indomethacin and IL-12 to mice bearing colon-26 carcinoma.
- Assessment of tumor growth retardation and mouse survival rates.
- Evaluation of angiogenesis inhibition as a potential mechanism.
Main Results:
- Combined treatment significantly enhanced anti-tumor activity compared to individual agents.
- Retardation of tumor growth and prolongation of mouse survival were observed.
- Complete tumor regression was achieved in some treated mice.
Conclusions:
- The combination of indomethacin and IL-12 demonstrates potent anti-tumor effects against colon-26 carcinoma.
- Inhibition of angiogenesis appears to be a key mechanism underlying the observed therapeutic benefits.
- This combination therapy holds promise for colorectal cancer treatment.